The tests are intended for infectious and chronic disease detection and diagnosis as well as to aid in routine health monitoring.

NEW YORK – The Centers for Medicare & Medicaid Services issued a request for information Thursday seeking public input on potential updates to the Clinical Laboratory Improvement Amendments of 1988 ...

NEW YORK – Congress on Tuesday passed an appropriations bill that includes a provision to again delay cuts to reimbursements to clinical laboratories under the Protection Access to Medicare Act (PAMA) ...

Abbott said on Thursday that its second quarter Diagnostics sales grew 42 percent to $3.09 billion compared to $2.17 billion in the year-ago quarter, helped along by its acquisition of Exact Sciences ...

Helio Genomics has appointed Parminder Bhatia to its board of directors. He is SVP of artificial intelligence at Edwards Lifesciences. Bhatia was also chief AI officer at GE Healthcare, and before ...

Alamar Biosciences has launched its eMTBR-Tau immunoassay for eMTBR-Tau, a plasma biomarker that is associated with tau-tangle pathology and is being explored as a possible measure of cognitive ...

The Alzheimer's Drug Discovery Foundation (ADDF) said on Monday that it has partnered with the Michael J. Fox Foundation (MJFF) to develop minimally invasive biomarkers for Parkinson's and Alzheimer's ...

Of the roughly 1 million disputes taken through the law's arbitration process in Q2 2025, around 129,000 were for lab codes, with payments for basic tests averaging hundreds of dollars.

Last week, readers were most interested in a story about Roche's blood-based IGRA test for latent TB getting CE marking.

Roche announced on Tuesday that it its Cobas hepatitis D test has been CE marked and the company is launching it in countries that accept the designation. The high-throughput test is intended for the ...

Under the policy, blood-based tests may be eligible for coverage if they either are cleared or approved by the US FDA or measure phosphorylated-tau 217.

Sapphiros will use the funding to develop its molecular diagnostic platform for biothreat and emerging infectious disease detection in point-of-care settings.